Treatment Outcomes in Patients with Recurrent Adrenocortical Carcinoma-Reference-Cited by-同舟云学术

Treatment Outcomes in Patients with Recurrent Adrenocortical Carcinoma

Published:2024-09-02 Issue: Volume: Page:1-7
ISSN:0743-5800
Container-title:Endocrine Research
language:en
Short-container-title:Endocrine Research

Author:

Dojcinovic Tamara¹²^ORCID,Tomsic Karin Zibar³^ORCID,Vodanovic Ivana Dora³^ORCID,Dusek Tina³⁴^ORCID,Kraljevic Ivana³⁴^ORCID,Nekic Anja Barac³^ORCID,Polovina Tanja Skoric³^ORCID,Knezevic Nikola⁴⁵^ORCID,Alduk Ana Marija⁴⁶^ORCID,Golubic Zrna Antunac⁷^ORCID,Kastelan Darko³⁴^ORCID

Affiliation:

1. Department of Endocrinology of the Internal medicine clinic, University Clinical Centre of the Republic of Srpska, Banja Luka, Bosnia and Herzegovina

2. School of Medicine, University of Banja Luka, Banja Luka, Bosnia and Herzegovina

3. Department of Endocrinology, University Hospital Center Zagreb, Zagreb, Croatia

4. School of Medicine, University of Zagreb, Zagreb, Croatia

5. Department of Urology, University Hospital Centre Zagreb, Zagreb, Croatia

6. Department of Radiology, University Hospital Centre Zagreb, Zagreb, Croatia

7. Department of Oncology, University Hospital Centre Zagreb, Zagreb, Croatia

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/07435800.2024.2397561

Reference18 articles.

1. European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors

2. What Is the Optimal Duration of Adjuvant Mitotane Therapy in Adrenocortical Carcinoma? An Unanswered Question

3. Approach to patients with European Network for the Study of Adrenal Tumor stages I and II adrenocortical carcinomas

4. Adjuvant mitotane versus surveillance in low-grade, localised adrenocortical carcinoma (ADIUVO): an international, multicentre, open-label, randomised, phase 3 trial and observational study

5. Longitudinal patterns of recurrence in patients with adrenocortical carcinoma